19
Participants
Start Date
May 3, 2023
Primary Completion Date
March 8, 2028
Study Completion Date
January 9, 2029
Tepotinib
Tepotinib hydrochloride hydrate will be supplied as film coated tablets. The 250 mg oval, white-pink film-coated tablets contain the excipients mannitol, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and Opadry II pink. All formulations are intended for oral administration. Refer to pharmacy manual for formulation and strength information.
Pembrolizumab
"Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material."
RECRUITING
DDU, Royal Marsden Hospital NHS Foundation Trust, Sutton
NOT_YET_RECRUITING
University College London Hospitals NHS Foundation Trust, London
RECRUITING
Lung Unit, Royal Marsden Hospital NHS Foundation Trust, London
RECRUITING
The Christie NHS Foundation Trust, Manchester
Merck Sharp & Dohme LLC
INDUSTRY
Merck KGaA, Darmstadt, Germany
INDUSTRY
Institute of Cancer Research, United Kingdom
OTHER